Skip to search formSkip to main contentSkip to account menu

cisplatin/cyclophosphamide/dexamethasone/doxorubicin/etoposide/thalidomide

Known as: CDDP/CTX/DM/DOX/THAL/VP-16, DTPACE 
A combination of agents containing cisplatin, cyclophosphamide, dexamethasone, doxorubicin, etoposide and thalidomide.
National Institutes of Health

Related topics

Related topics

7 relations
CisplatinCyclophosphamideDexamethasoneDoxorubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement
Dear Editor, Multiple myeloma (MM) is an incurable malignant plasma cell tumor. Although the introduction of proteasome inhibitor… 
Review
2015
Review
2015
Quality of Life in Multiple Myeloma: Validation of the Turkish Version of the Qlq-My20 Instrument
2008
2008
[Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
OBJECTIVE To investigate the efficacy and adverse reaction of bortezomib plus chemotherapy with or without stem cell… 
2006
2006
Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM).
Background: High-dose melphalan (MEL)-based autotransplants (AT) have significantly improved complete response rates (CR) and… 
2003
2003
DTPACE: A n E ffective, N ovel C ombination C hemotherapy W ith Thalidomide f or P reviously T reated P atients W ith M yeloma
Purpose: To improve outcome in previously treated patients (at least two cycles of standard therapy) with multiple myeloma… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)